Aptevo Therapeutics (APVO) EBT Margin (2015 - 2022)
Aptevo Therapeutics (APVO) posted EBT Margin of 190.56% for Q1 2022, down 72.87% sequentially from 110.23% in Q4 2021, and up 27324.0% YoY from N/an in Q1 2021.
Aptevo Therapeutics (APVO) EBT Margin (2015 - 2022) Analysis & Trends
Aptevo Therapeutics has reported EBT Margin for 8 years, with the latest figure at 190.56% in Q1 2022.
- Quarterly EBT Margin rose 27324.0% year-over-year to 190.56% in Q1 2022, while the trailing twelve-month figure through Dec 2022 was 1001.45% (down 75957.0% YoY) and the FY2022 annual result came in at 1029.0%, down 84351.0% from the prior year.
- EBT Margin eased to 190.56% in Q1 2022 per APVO's latest filing, from 110.23% in the prior quarter.
- Over five years, EBT Margin peaked at 88.59% in Q4 2019 and troughed at 1605.71% in Q2 2020.
- A 5-year average of 344.14% and a median of 248.36% in 2018 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2020 and 2021: EBT Margin slumped 134264 bps in 2020, then jumped 133387 bps in 2021.
- Over 5 years, EBT Margin stood at 236.59% in 2018, then soared by 63 bps to 88.59% in 2019, then plunged by 295 bps to 349.73% in 2020, then soared by 68 bps to 110.23% in 2021, then sank by 73 bps to 190.56% in 2022.
- According to Business Quant data, EBT Margin over the past three periods registered 190.56%, 110.23%, and 194.07% for Q1 2022, Q4 2021, and Q3 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 12.09% |
| 10 | Aptevo Therapeutics | 3.34 Mn | -6.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -190.56% |
| Dec 31, 2021 | -110.23% |
| Sep 30, 2021 | -194.07% |
| Jun 30, 2021 | -271.84% |
| Mar 31, 2021 | -463.80% |
| Dec 31, 2020 | -349.73% |
| Sep 30, 2020 | -474.91% |
| Jun 30, 2020 | -1,605.71% |
| Dec 31, 2019 | -88.59% |
| Sep 30, 2019 | -134.10% |
| Jun 30, 2019 | -263.07% |
| Mar 31, 2019 | -188.89% |
| Sep 30, 2018 | -236.59% |
| Jun 30, 2018 | -248.36% |
| Mar 31, 2018 | -341.64% |
| Sep 30, 2017 | -174.72% |
| Jun 30, 2017 | -430.03% |
| Mar 31, 2017 | -585.29% |
| Dec 31, 2016 | -170.44% |
| Sep 30, 2016 | -3,232.14% |